|
Uncertainty about what Britain's relations with the EU will look
like after March 2019 are hurting investment in the world's
fifth largest economy. Businesses most fear a situation where
there is no deal at all.
AstraZeneca Chairman Leif Johansson said the firm wanted "at
least three years" as a transition period, "and very early in
that period, we need to know what to expect in years four, five
and six," he said told the Swedish daily Dagens Nyheter.
British Finance Minister Philip Hammond, speaking during the
ruling Conservative Party's annual conference, told BBC radio on
Monday that uncertainty was hurting business confidence but said
the government's proposal for a two-year transition would help.
[nS8N1JA01C]
Foreign Secretary Boris Johnson has said the transition period
must not last more than two years.
Johansson said AstraZeneca, created from a merger between
Sweden's Astra and Britain's Zeneca in 1999, did not expect a
"cliff-edge" exit without a deal but said it remained a risk.
"There is a logic among the political leadership that you just
don't back down until the last minute." he said. "Then, finally,
after pulling an all-nighter, you get to a result."
AstraZeneca was preparing for a situation where there was no
deal but did not yet have concrete plans, Johansson said.
(Reporting by Simon Johnson; Editing by Edmund Blair)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
